Information has been received from a consumer concerning her son, a 17 year old male with urticaria and a history of asthma was vaccinated with a dose of VARIVAX (Merck) (lot # 665586/1227Y) in the shoulder on 17-MAR-2010. He also received VAQTA (lot # 666030/1397Y) (MSD) and "MCV4 meningitis vaccine produced by SANOFI AVENTIS". The reporter's son did not develop any rash. On 30-MAR-2010 the reporter's daughter, a 15 year old female patient with asthma, no drug allergies and a prior episode of anemia developed chickenpox. The patient was receiving amoxicillin and mupirocin as of 31-MAR-2010. The patient was also receiving albuterol. The patient sought medical attention by office visit. The chickenpox was confirmed by a physician. There were no lab diagnostics studies performed. At the time of the report, the patient had not recovered. Follow up information has been received the consumer reporting that on 17-MAR-2010 her daughter babysat a 1 year old boy who received a Varicella Vaccine (unspecified) on 05-MAR-2010. No additional information provided. Follow up information has been received from a physician and registered nurse concerning a 15 year old female patient with no known drug allergies. The patient was enrolled in the Varicella Zoster Virus Identification Program to identify if VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the Merck vaccine VZV strain. On 02-APR-2010, a sample was taken from a vesicle lesion and a scab. On 05-APR-2010, the sample was sent to the laboratory. It was noted that the patient's brother received the second dose of VARIVAX (Merck) (lot # 665586/1227Y) on 17-MAR-2010 and the patient developed chickenpox 2 weeks after exposure. The PCR result from the vesicle lesion and the scab specimen identified the presence of WT VZV. Follow up information was received from two registered nurses: The patient was seen in the office on 30-MAR-2010 with questionable chickenpox. On 01-MAR-2010 the patient was seen in office with more lesions and a physician confirmed that the patient had classic chickenpox. The patient had not been vaccinated with VARIVAX (Merck), but did have a light chickenpox when she was younger, when she was at 4 years old prior to kindergarten. The patient's brother was vaccinated with a dose of VARIVAX (Merck) on 17-MAR-2010. The patient's brother did not experience any rashes or lesions since vaccination. The patient's brother had a case of chickenpox as a child. On 02-APR-2010, the patient was in the office and samples were collected. On 03-APR-2010, the patient developed a significant amount of lesions compared to when was seen on 02-APR-2010. The patient had chickenpox lesions on her entire body, face and in her mouth. The patient was not treated with any medication, just rest and lots of fluid. On 12-APR-2010 it was confirmed that 1 year old boy that the patient babysat on 17-MAR-2010 did have a rash on side at the time the patient cared for him. On 12-APR-2010 the baby's rash had likely healed. On 12-APR-2010, the patient was much better and had recovered. On 14-APR-2010, the patient was fully recovered, back to school and soccer and per her mother, "doing wonderful". Follow up information was received indicating that: The physician said the results of the specimen test showed that it was wild type and not from the vaccine and not a case of transmission and not an adverse event related to a vaccine. Additional information is not expected. The 1 year old boy that the patient babysat experienced a rash while on therapy with VARIVAX (Merck) (MSD, WAES 1004USA02804). The patient's brother experienced chickenpox while on therapy with VARIVAX (Merck) (MSD, WAES 1004USA02390). The patient's sister experienced chickenpox and secondary transmission (Merck) (WAES 1004USA02391). This is a consolidation of two reports concerning the same patient.